MA44665A - Des anti-sirpa anticorps nouvelles et leurs utilisations therapeutiques - Google Patents

Des anti-sirpa anticorps nouvelles et leurs utilisations therapeutiques

Info

Publication number
MA44665A
MA44665A MA044665A MA44665A MA44665A MA 44665 A MA44665 A MA 44665A MA 044665 A MA044665 A MA 044665A MA 44665 A MA44665 A MA 44665A MA 44665 A MA44665 A MA 44665A
Authority
MA
Morocco
Prior art keywords
therapeutic uses
new anti
sirpa antibodies
sirpa
antibodies
Prior art date
Application number
MA044665A
Other languages
English (en)
Other versions
MA44665B1 (fr
Inventor
Vanessa Gauttier
Caroline Mary
Sabrina Pengam
Nicolas Poirier
Virginie Thepenier
Bernard Vanhove
Original Assignee
Ose Immunotherapeutics
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ose Immunotherapeutics filed Critical Ose Immunotherapeutics
Priority claimed from EP17718881.0A external-priority patent/EP3443010B1/fr
Publication of MA44665A publication Critical patent/MA44665A/fr
Publication of MA44665B1 publication Critical patent/MA44665B1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2827—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56966—Animal cells
    • G01N33/56972—White blood cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/74—Inducing cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/75—Agonist effect on antigen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/80—Immunoglobulins specific features remaining in the (producing) cell, i.e. intracellular antibodies or intrabodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2318/00—Antibody mimetics or scaffolds
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/70503—Immunoglobulin superfamily, e.g. VCAMs, PECAM, LFA-3
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/70596—Molecules with a "CD"-designation not provided for elsewhere in G01N2333/705

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Microbiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Virology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Zoology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
MA44665A 2016-04-14 2017-04-14 Des anti-sirpa anticorps nouvelles et leurs utilisations therapeutiques MA44665B1 (fr)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201662322707P 2016-04-14 2016-04-14
EP17305182 2017-02-17
EP17718881.0A EP3443010B1 (fr) 2016-04-14 2017-04-14 Des anti-sirpa anticorps nouvelles et leurs utilisations therapeutiques
PCT/EP2017/059071 WO2017178653A2 (fr) 2016-04-14 2017-04-14 Nouveaux anticorps anti-sirpa et leurs applications thérapeutiques

Publications (2)

Publication Number Publication Date
MA44665A true MA44665A (fr) 2019-02-20
MA44665B1 MA44665B1 (fr) 2024-11-29

Family

ID=65529144

Family Applications (1)

Application Number Title Priority Date Filing Date
MA44665A MA44665B1 (fr) 2016-04-14 2017-04-14 Des anti-sirpa anticorps nouvelles et leurs utilisations therapeutiques

Country Status (24)

Country Link
US (3) US11279766B2 (fr)
EP (1) EP4438626A3 (fr)
JP (2) JP7491666B2 (fr)
KR (1) KR102355240B1 (fr)
CN (1) CN115785272A (fr)
CL (1) CL2018002898A1 (fr)
DK (1) DK3443010T3 (fr)
ES (1) ES2990971T3 (fr)
FI (1) FI3443010T3 (fr)
HR (1) HRP20241316T1 (fr)
HU (1) HUE068840T2 (fr)
IL (1) IL262251B2 (fr)
LT (1) LT3443010T (fr)
MA (1) MA44665B1 (fr)
MD (1) MD3443010T2 (fr)
MX (1) MX2018012434A (fr)
PH (1) PH12018550160B1 (fr)
PL (1) PL3443010T3 (fr)
RS (1) RS66062B1 (fr)
SA (1) SA518400237B1 (fr)
SI (1) SI3443010T1 (fr)
SM (1) SMT202400438T1 (fr)
UA (1) UA126658C2 (fr)
ZA (1) ZA201806293B (fr)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SMT202400438T1 (it) * 2016-04-14 2024-11-15 Ose Immunotherapeutics Nuovi anticorpi anti-sirpa e loro applicazioni terapeutiche
JOP20190009A1 (ar) 2016-09-21 2019-01-27 Alx Oncology Inc أجسام مضادة ضد بروتين ألفا منظم للإشارات وطرق استخدامها
CN111448210B (zh) * 2017-07-26 2024-05-14 四十七公司 抗SIRP-α抗体及相关方法
JP7395471B2 (ja) * 2017-10-13 2023-12-11 オーセ イミュノセラピューティクス 改変抗ＳＩＲＰａ抗体及びその使用
CN112105646A (zh) 2018-03-13 2020-12-18 Ose免疫疗法 抗人SIRPa v1抗体的用途和生产抗SIRPa v1抗体的方法
US11292850B2 (en) 2018-03-21 2022-04-05 ALX Oncology Inc. Antibodies against signal-regulatory protein α and methods of use
PE20211491A1 (es) 2018-09-27 2021-08-11 Celgene Corp PROTEINAS DE FIJACION A SIRPa Y METODOS DE USO DE ESTAS
US11591390B2 (en) 2018-09-27 2023-02-28 Celgene Corporation SIRP-α binding proteins and methods of use thereof
MX2022004370A (es) 2019-10-18 2022-05-06 Forty Seven Inc Terapias de combinacion para tratar sindromes mielodisplasicos y leucemia mieloide aguda.
WO2021087064A1 (fr) 2019-10-31 2021-05-06 Forty Seven, Inc. Traitement d'un cancer du sang basé sur une thérapie anti-cd47 et anti-cd20
CN112574310B (zh) 2020-12-11 2023-05-05 浙江博锐生物制药有限公司 抗SIRPα抗体及其用途
KR102896511B1 (ko) * 2022-09-07 2025-12-08 주식회사 시프트바이오 SIRPα 변이체에 특이적으로 결합하는 항체

Family Cites Families (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19742706B4 (de) 1997-09-26 2013-07-25 Pieris Proteolab Ag Lipocalinmuteine
AU1701001A (en) 1999-11-30 2001-06-12 Eberhard-Karls-Universitat Tubingen Universitatsklinikum Antibodies against signal regulator proteins
US20100215640A1 (en) 2003-04-24 2010-08-26 The University Of North Carolina At Chapel Hill Method for inhibiting cellular activation by insulin-like growth factor-1
US8613922B2 (en) 2003-04-24 2013-12-24 The University Of North Carolina At Chapel Hill Methods for inhibiting diabetic retinopathy with an antibody against integrin associated protein (IAP)
JP3936673B2 (ja) 2003-06-02 2007-06-27 国立大学法人群馬大学 Ｃｄ４７部分ペプチドと抗ｓｈｐｓ−１モノクロナール抗体
EA019344B1 (ru) 2005-07-01 2014-03-31 МЕДАРЕКС, Эл.Эл.Си. Человеческие моноклональные антитела против лиганда-1 запрограммированной гибели клеток (pd-l1) и их применения
EP1930342B1 (fr) 2006-12-04 2012-01-25 Institut Pasteur OB-fold utilisé en tant que base pour l'ingénierie de nouveaux liants spécifiques
CA2702217A1 (fr) 2007-10-11 2009-04-16 Jayne Danska Modulation de l'interaction sirpa - cd47 pour augmenter la prise de greffe des cellules souches hematopoietiques humaines et leurs composes
EP3424525A1 (fr) 2007-10-12 2019-01-09 Massachusetts Institute Of Technology Nanotechnologie de vaccin
FI3056514T4 (fi) 2008-01-15 2025-10-06 Univ Leland Stanford Junior Menetelmät cd47:n välittämän fagosytoosin manipuloimiseksi
EP2111869A1 (fr) 2008-04-23 2009-10-28 Stichting Sanquin Bloedvoorziening Compositions et procédés pour renforcer le système immunitaire
HUE065752T2 (hu) 2008-12-09 2024-06-28 Hoffmann La Roche Anti-PD-L1 antitestek és felhasználásuk T-sejt funkció elõsegítésére
US10907209B2 (en) 2009-05-15 2021-02-02 University Health Network Compositions and methods for treating hematological cancers targeting the SIRPα CD47 interaction
GB201015765D0 (en) 2010-09-21 2010-10-27 Immatics Biotechnologies Gmbh Use of myeloid cell biomarkers for the diagnosis of cancer
US8883497B2 (en) 2011-04-28 2014-11-11 University Of Southern California Human myeloid derived suppressor cell cancer markers
US20140193408A1 (en) * 2011-06-16 2014-07-10 Novartis Ag Soluble proteins for use as therapeutics
US20140242095A1 (en) * 2011-10-19 2014-08-28 University Health Network Antibodies and antibody fragments targeting sirp-alpha and their use in treating hematologic cancers
KR101981873B1 (ko) 2011-11-28 2019-05-23 메르크 파텐트 게엠베하 항-ｐｄ-ｌ1 항체 및 그의 용도
EP3766511A1 (fr) 2012-01-17 2021-01-20 The Board of Trustees of the Leland Stanford Junior University Réactifs sirp-alpha de haute affinité
WO2014123580A1 (fr) 2013-02-06 2014-08-14 Inhibrx Llc Anticorps cd47 n'induisant ni l'appauvrissement en globules rouges ni l'appauvrissement en plaquettes
US10570204B2 (en) 2013-09-26 2020-02-25 The Medical College Of Wisconsin, Inc. Methods for treating hematologic cancers
AU2015229448B2 (en) * 2014-03-11 2020-09-03 The Board Of Trustees Of The Leland Stanford Junior University Anti SIRP-alpha antibodies and Bi-specific Macrophage Enhancing antibodies
CN105085679B (zh) * 2014-04-25 2019-01-11 上海津曼特生物科技有限公司 全人源抗rankl抗体
EP3012271A1 (fr) 2014-10-24 2016-04-27 Effimune Procédé et compositions pour induire la différenciation de cellule suppressives dérivées de myéloïde pour traiter le cancer et les maladies infectieuses
WO2016205042A1 (fr) 2015-06-16 2016-12-22 The Board Of Trustees Of The Leland Stanford Junior University Anticorps agonistes de sirpα
EP4186927B1 (fr) 2015-10-21 2025-04-23 Ose Immunotherapeutics Procédés et compositions de modification de la polarisation des macrophages en cellules pro-inflammatoires pour traiter le cancer
SMT202400438T1 (it) 2016-04-14 2024-11-15 Ose Immunotherapeutics Nuovi anticorpi anti-sirpa e loro applicazioni terapeutiche
JOP20190009A1 (ar) 2016-09-21 2019-01-27 Alx Oncology Inc أجسام مضادة ضد بروتين ألفا منظم للإشارات وطرق استخدامها
JP7173971B2 (ja) 2016-12-09 2022-11-16 アレクトル エルエルシー 抗ＳＩＲＰ－α抗体及びその使用方法
PT3443010T (pt) 2017-02-17 2024-10-21 Ose Immunotherapeutics Novos anticorpos anti-sirpa e suas aplicações terapêuticas
MX2019012233A (es) * 2017-04-13 2020-01-14 Aduro Biotech Holdings Europe Bv Anticuerpos anti-sirpa.
HUE067040T2 (hu) 2017-05-16 2024-09-28 Byondis Bv Anti-SIRPalfa antitestek
CN111448210B (zh) 2017-07-26 2024-05-14 四十七公司 抗SIRP-α抗体及相关方法
JP7395471B2 (ja) 2017-10-13 2023-12-11 オーセ イミュノセラピューティクス 改変抗ＳＩＲＰａ抗体及びその使用
CN112105646A (zh) 2018-03-13 2020-12-18 Ose免疫疗法 抗人SIRPa v1抗体的用途和生产抗SIRPa v1抗体的方法
US11292850B2 (en) 2018-03-21 2022-04-05 ALX Oncology Inc. Antibodies against signal-regulatory protein α and methods of use
TW202448946A (zh) 2018-05-25 2024-12-16 美商阿列克特有限責任公司 抗-sirpa 抗體及其使用方法
AU2019302152B2 (en) 2018-07-10 2025-07-10 Daiichi Sankyo Company, Limited Anti-sirpalpha antibody
WO2020033646A1 (fr) 2018-08-08 2020-02-13 Orionis Biosciences, Inc. PROTÉINES CHIMÈRES CIBLÉES SUR SIRP1α ET LEURS UTILISATIONS
PE20211491A1 (es) 2018-09-27 2021-08-11 Celgene Corp PROTEINAS DE FIJACION A SIRPa Y METODOS DE USO DE ESTAS
WO2020102422A1 (fr) 2018-11-14 2020-05-22 Arch Oncology, Inc. ANTICORPS SIRPα THÉRAPEUTIQUES
CA3118966A1 (fr) 2018-11-15 2020-05-22 Byondis B.V. Anticorps anti-sirpa humanises
WO2020180811A1 (fr) 2019-03-04 2020-09-10 Qilu Puget Sound Biotherapeutics Corporation ANTICORPS ANTI-SIRPα
WO2021032078A1 (fr) 2019-08-20 2021-02-25 Elpiscience (Suzhou) Biopharma, Ltd. Nouveaux anticorps anti-sirpa
CN111635458B (zh) 2020-03-20 2026-02-17 健信生物科技(宁波)有限公司 靶向Sirpα的抗体或其抗原结合片段及其制备和应用
CN112010979B (zh) 2020-08-21 2022-05-10 博奥信生物技术（南京）有限公司 一种抗人SIRPα单克隆抗体及其用途
CN111995682B (zh) 2020-08-21 2022-05-10 博奥信生物技术（南京）有限公司 抗人SIRPα单克隆抗体及其用途
CN112574310B (zh) 2020-12-11 2023-05-05 浙江博锐生物制药有限公司 抗SIRPα抗体及其用途

Also Published As

Publication number Publication date
JP7491666B2 (ja) 2024-05-28
SA518400237B1 (ar) 2025-06-02
KR102355240B1 (ko) 2022-01-25
HUE068840T2 (hu) 2025-01-28
US20220281991A1 (en) 2022-09-08
ES2990971T3 (es) 2024-12-02
PH12018550160A1 (en) 2019-03-11
CL2018002898A1 (es) 2018-12-14
EP4438626A2 (fr) 2024-10-02
RS66062B1 (sr) 2024-11-29
MA44665B1 (fr) 2024-11-29
FI3443010T3 (fi) 2024-10-10
MX2018012434A (es) 2019-06-06
KR20180134397A (ko) 2018-12-18
SMT202400438T1 (it) 2024-11-15
LT3443010T (lt) 2024-10-25
HRP20241316T1 (hr) 2024-12-20
MD3443010T2 (ro) 2024-12-31
DK3443010T3 (da) 2024-09-30
IL262251B1 (en) 2023-05-01
JP2019520034A (ja) 2019-07-18
IL262251A (en) 2018-11-29
UA126658C2 (uk) 2023-01-11
NZ746545A (en) 2025-05-30
US20190127477A1 (en) 2019-05-02
US11279766B2 (en) 2022-03-22
ZA201806293B (en) 2023-06-28
CN115785272A (zh) 2023-03-14
IL262251B2 (en) 2023-09-01
SI3443010T1 (sl) 2025-01-31
US20250215108A1 (en) 2025-07-03
US12252546B2 (en) 2025-03-18
EP4438626A3 (fr) 2024-12-04
JP2022169504A (ja) 2022-11-09
JP7549626B2 (ja) 2024-09-11
PH12018550160B1 (en) 2024-07-03
PL3443010T3 (pl) 2025-02-03

Similar Documents

Publication Publication Date Title
FR25C1020I1 (fr) Anticorps thérapeutiques et leurs utilisations
EP3625263A4 (fr) Anticorps anti-galectine-9 et leurs utilisations
EP3504243A4 (fr) Anticorps anti-tim-3 et leurs utilisations
EP3383916A4 (fr) Anticorps anti-cd73 et leurs utilisations
EP3426288A4 (fr) Anticorps anti-pacap et leurs utilisations
EP3389702A4 (fr) Anticorps anti-lag-3 et leurs utilisations
MA46704A (fr) Anticorps anti-pyroglutamate- amyloïde-beta et leurs utilisations
EP3759143A4 (fr) Anticorps anti-tigit et leurs utilisations
MA47789A (fr) Anticorps anti-phf-tau et leurs utilisations
MA49683A (fr) Anticorps anti-cd8 et leurs utilisations
EP3661965A4 (fr) Anticorps anti-cd47 et leurs utilisations
MA49537A (fr) Anticorps anti-lag3 et leurs utilisations
MA44665A (fr) Des anti-sirpa anticorps nouvelles et leurs utilisations therapeutiques
MA45235A (fr) Anticorps anti-c5 et leurs utilisations
MA46708A (fr) Anticorps anti-pd1 et leurs utilisations
EP3377102C0 (fr) Anticorps anti-pd-1 et leurs utilisations thérapeutiques
EP3283516A4 (fr) Anticorps anti-pacap et leurs utilisations
MA53184A (fr) Anticorps anti-ox40 et leurs utilisations
MA49886A (fr) Anticorps anti-par2 et leurs utilisations
MA45125A (fr) Anticorps anti-alpha-synucléine et leurs utilisations
EP3362482A4 (fr) Anticorps anti-pcsk9 et leurs utilisations
EP3645563A4 (fr) Anticorps anti-fam19a5 et leurs utilisations
MA43567A (fr) Anticorps pacap et leurs utilisations
MA45233A (fr) Anticorps anti-gitr et leurs utilisations
EP3672987A4 (fr) Anticorps anti-apéline et leurs utilisations